Abolis Biotechnologies, a pioneering French biotech company founded in 2014, is thrilled to announce the successful raising of €35 million (approximately $37.5 million) in its latest funding round. This significant investment will fuel Abolis's mission to transform industries through innovative biotechnological solutions that align with the principles of ecological sustainability. With a dedicated team of over 54 experts from diverse fields including biology, fermentation, robotics, and analytics, Abolis is leading the charge in rethinking production models across a spectrum of sectors, from food and healthcare to cosmetics and chemicals. The newly acquired funds will enhance Abolis’s capacity to harness the potential of micro-organisms to develop tailor-made industrial solutions that serve as environmentally-friendly alternatives to traditional petrochemical products. By prioritizing the use of renewable raw materials, relocating essential production to secure supply chains, and creating biocompatible products that minimize toxicity, Abolis aims to help industries successfully navigate the ecological transition. This funding marks a pivotal moment for the company, reaffirming its commitment to pioneering solutions that not only address the pressing challenges of greenhouse gas emissions but also strive to create a better future in harmony with nature. With a foundation rooted in humanist values and scientific rigor, Abolis is poised to continue its innovative journey, redefining the manufacturing landscape and inspiring others along the way.








